Apomorphine sublingual film - Cynapsus

Drug Profile

Apomorphine sublingual film - Cynapsus

Alternative Names: APL-130277

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Adagio Pharmaceuticals
  • Developer Cynapsus Therapeutics
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 24 Oct 2016 Sunovion Pharmaceuticals intends to submit NDA to the US FDA during 1H 2017
  • 21 Oct 2016 Sunovion Pharmaceuticals acquires Cynapsus Therapeutics
  • 31 Aug 2016 Cynapsus plans a clinical trial for Parkinson’s disease in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top